Key Points {#FPar1}
==========

Exposure to *d*- and *l*-amphetamine was not altered by consuming a high-fat meal before taking SHP465 mixed amphetamine salts (MAS) or by sprinkling the contents of a SHP465 MAS capsule over applesauce, demonstrating that SHP465 MAS capsules can be swallowed whole with or without food or the contents of an SHP465 MAS capsule can be sprinkled on applesauce.SHP465 MAS was generally well tolerated when administered as a single 50-mg dose in healthy adults, with a profile that was consistent with previously reported effects in adults with attention-deficit/hyperactivity disorder.

Introduction {#Sec1}
============

SHP465 mixed amphetamine salts (MAS) extended release (Mydayis^®^; Shire, Lexington, MA, USA) is a once-daily, single-entity MAS capsule product for oral administration approved in USA for the treatment of attention-deficit/hyperactivity disorder (ADHD) in individuals aged 13 years and older \[[@CR1]\]. SHP465 MAS contains equal amounts (by weight) of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate monohydrate; this results in a 3:1 mixture of *d*-amphetamine to *l*-amphetamine. Each SHP465 MAS capsule contains three types of drug-releasing beads (one immediate-release bead and two different types of delayed-release beads) in a 1:1:1 ratio \[[@CR1]\].

The short-term efficacy and safety of SHP465 MAS in adults with ADHD have been examined in multiple phase III studies \[[@CR2]--[@CR4]\]. In a 7-week dose-optimization study, significantly greater reductions from baseline in the ADHD Rating Scale, Version IV total score were observed with SHP465 MAS (12.5--75 mg) than with placebo in adults with ADHD \[[@CR3]\]. In 4- and 7-week forced-dose studies, SHP465 MAS produced significantly greater reductions in the ADHD Rating Scale With Adult Prompts (12.5 and 37.5 mg) \[[@CR4]\] and the ADHD Rating Scale, Version IV (25, 50, and 75 mg) \[[@CR2]\] total scores than placebo in adults with ADHD. Across short-term efficacy studies \[[@CR2]--[@CR4]\], the safety and tolerability profile of SHP465 MAS was consistent with that of other long-acting psychostimulants.

Medication adherence is linked to several factors \[[@CR5]\], including ease of drug administration \[[@CR6], [@CR7]\]. One method to increase the ease of taking medication is to eliminate the need to swallow a tablet or pill, which is an impediment to adherence in individuals who find it difficult to swallow tablets or capsules \[[@CR6]--[@CR8]\]. Individuals who experience difficulty swallowing tablets or capsules often alter the dosage form (e.g., crushing/chewing tablets, emptying capsule contents into a soft food) to ease administration, which may alter the agent's stability, efficacy, and safety \[[@CR6], [@CR7]\]. Further, food--drug interactions can affect the bioavailability of drugs, resulting in therapeutic failure from decreased bioavailability or poor tolerability owing to increased bioavailability \[[@CR9], [@CR10]\]. High-fat foods in particular have the potential to influence drug bioavailability by altering drug absorption in the gastrointestinal tract \[[@CR9], [@CR10]\]. Helping to address the issues associated with swallowing capsules or tablets, the administration directions for several medications approved for the treatment of ADHD (e.g., MAS extended release, methylphenidate extended release, dexmethylphenidate hydrochloride extended release, lisdexamfetamine) indicate that the contents of capsules may be sprinkled onto applesauce \[[@CR11]--[@CR14]\] or mixed with yogurt or orange juice \[[@CR15]\] and specify that administration after a high-fat meal does not alter bioavailability \[[@CR11], [@CR12], [@CR14], [@CR15]\].

This study evaluated the pharmacokinetics of *d*- and *l*-amphetamine when SHP465 MAS was administered after a high-fat meal or after the capsule contents were sprinkled on applesauce relative to consumption of an intact SHP465 MAS capsule in fasting healthy adults. The primary objective of the study was to assess the effect of a high-fat meal on the bioavailability of 50 mg of SHP465 MAS relative to the fasted state. Secondary study objectives included assessment of the bioavailability of 50 mg of SHP465 MAS after sprinkling the contents of an SHP465 MAS capsule over applesauce relative to the fasted state and the assessment of the safety and tolerability of 50 mg of SHP465 MAS.

Methods {#Sec2}
=======

Study Design and Treatment {#Sec3}
--------------------------

This phase I, open-label, randomized, single-dose, three-way crossover study in healthy adults (aged 18--55 years) was conducted from 27 December, 2004, to 26 January, 2005. The study protocol and informed consent form were approved by the Covance Clinical Research Unit Institutional Review Board (Madison, WI, USA). The study protocol was conducted in accordance with the principles of the 18th World Medical Assembly and amendments of the 29th, 35th, 41st, and 48th World Medical Assemblies and the International Conference on Harmonization Good Clinical Practices.

The study consisted of screening, baseline, and three single-dose treatment periods; each single-dose treatment period was separated by a ≥ 7-day washout period (Fig. [1](#Fig1){ref-type="fig"}). At screening, which occurred within 28 days of check-in for the first treatment period, prospective participants received written information and an explanation of the study. All participants were required to give informed consent after having received this information; no study procedures were conducted before consent was provided.Fig. 1Study design. Fasted condition: 50 mg of SHP465 mixed amphetamine salts (MAS) as an intact capsule after a fast of ≥ 10 h. Fed condition: 50 mg of SHP465 MAS as an intact capsule 30 min following the start of a high-fat meal. Sprinkled condition: contents of a 50-mg SHP465 MAS capsule sprinkled on applesauce after a fast of ≥ 10 h

Screening procedures included assessment of participant eligibility based on inclusion/exclusion criteria; collection of demographic, medical and medication history, and physical examination data; assessment of vital signs (after the participant was seated and at rest for 5 min) and of a 12-lead electrocardiogram (after 5 min of rest); laboratory tests (hematology, serum biochemistry, urinalysis); a serum pregnancy test for women of child-bearing age; and a urine screen for alcohol and drugs of abuse.

After screening, eligible participants were randomized to a treatment sequence, using a randomization schedule employing two 3 × 3 Latin squares with each treatment condition (Fig. [1](#Fig1){ref-type="fig"}). Study participants were randomized into six dosing sequence groups (ABC, ACB, BAC, BCA, CAB, and CBA), where A was the fasted condition, B was the fed condition, and C was the sprinkled condition. Two or three participants were included in each sequence. For the fasted condition, 50 mg of SHP465 MAS was administered as an intact capsule after a fast of ≥ 10 h (reference treatment). In the fed condition, 50 mg of SHP465 MAS was given as an intact capsule 30 min after the start of a standard high-fat meal (approximately 800--1000 calories, with approximately 50% of the calories from fat). In the sprinkled condition, 50 mg of SHP465 MAS was administered after a fast of ≥ 10 h, with the contents of the capsule ingested immediately after being sprinkled on a tablespoon of applesauce. Under each condition, SHP465 MAS was to be administered to the participant at approximately 8:00 a.m. with 8 ounces of water. Following treatment, all participants were required to fast for 4 h, at which time a meal was provided. Participants were allowed to take naps during the post-dose period, with the exception of the first 4 h post-dose, and were not restricted from participating in organized activities. However, an increase above their usual activity level prior to and during the 60 h following dosing was prohibited. Participants were also prohibited from consuming foods or beverages containing alcohol, caffeine/xanthine, or ascorbic acid for 48 h before the baseline visit through 60 h post-dose.

On the morning before a scheduled treatment period, eligible participants were admitted to the clinic and the following procedures were conducted: confirmation of eligibility based on inclusion/exclusion criteria, a physical examination, an assessment of vital signs (after 5 min of rest) and of a 12-lead electrocardiogram (at 10:00 a.m., 12:00 p.m., and 4:00 p.m. after 5 min of rest), clinical laboratory tests, a serum pregnancy test for women of child-bearing age, a urine screen for alcohol and drugs of abuse, and assessment of concomitant medication and adverse events (AEs). Participants remained at the clinic until completion of the 60-h post-dose blood collection. All participants received a follow-up telephone call 30 ± 5 days after the last exposure to the study drug to assess AEs.

Participants {#Sec4}
------------

A total of 16 healthy adult (aged 18‒55 years) men and women with no clinically significant abnormal results and a body mass index between 20 and 29 kg/m^2^ were eligible to participate in the study. Women were required to be postmenopausal, surgically sterile, or to have a negative serum pregnancy test before entering the study and were required to be using or agree to use acceptable contraception methods for the duration of the study and for 30 days after the last dose of study drug.

Individuals were excluded from the study if they had a current or recurrent disease that could affect the action, absorption, or disposition of SHP465 MAS or if they had any current disorder or medical history that may require treatment, reduce the likelihood of study completion, affect the validity of the study results, or present undue risk from the study drug or procedures or jeopardize the participant's safety. A history of uncontrolled hypertension, baseline systolic blood pressure (SBP) \> 139 mmHg or diastolic blood pressure (DBP) \> 89 mmHg, or any known or suspected structural cardiac abnormality was also exclusionary. Additional criteria for exclusion were a history of alcohol or other substance abuse or a positive urine screen for drugs of abuse; the use of nicotine-containing products in any form; the use of any prescription medication within 14 days of baseline, any over-the-counter medication within 7 days of baseline, any known enzyme-altering agents within 30 days of baseline (or during the study) that could alter the pharmacokinetics of SHP465 MAS, or any investigational drug within 30 days of enrollment; a known or suspected intolerance or hypersensitivity to amphetamines or any related drugs; and a known or suspected allergy to apples, applesauce, or any food items in the high-fat meal.

Endpoints {#Sec5}
---------

### Pharmacokinetics {#Sec6}

Blood samples for the determination of plasma amphetamine concentrations were collected 30 min pre-dose (hour 0); at hourly intervals up to 10 h post-dose; and at 12, 14, 16, 24, 36, 48, and 60 h post-dose. Pharmacokinetic parameters assessed included maximum plasma concentration (*C*~max~), time to *C*~max~ (*t*~max~), area under the plasma concentration--time curve from time 0 to the last measured time (AUC~0--last~) and from time 0 to infinity (AUC~0--inf~), terminal half-life (*t*~½~), and the terminal phase rate constant (*λ*~*z*~). The linear trapezoidal rule was used to calculate area under the curve. The pharmacokinetic parameters were calculated with non-compartmental techniques using WinNonlin^®^ Professional, Version 4.1 (Pharsight Corporation, Mountainview, CA, USA).

### Bioanalytical Methods {#Sec7}

Validated liquid chromatography with tandem mass spectrometry was used to evaluate *d-* and *l*-amphetamine levels. Plasma concentrations were calculated using an eight-point standard curve (0.5--75 ng/mL). Assay precision ranged from 0.8 to 6.2% for *d*-amphetamine and from 1.1--4.6% for *l-*amphetamine. Assay accuracy ranged from 90.8 to 108.1% for *d*-amphetamine and from 91.3 to 107.3% for *l-*amphetamine. Plasma samples \< 0.5 or \> 75 ng/mL were considered below the lower limit or above the upper limit of quantification, respectively. Samples were assayed simultaneously with calibration standards and quality-control samples that were prepared in a 0.5-mL aliquot of ethylenediaminetetraacetic acid human plasma.

Samples were extracted along with a deuterated, racemic, amphetamine internal standard by liquid--liquid extraction into hexane, followed by back extraction into acid; sodium ethylenediaminetetraacetic acid was used as an anticoagulant. Following realkalinization, the analytes were derivatized with benzoyl chloride, and the benzoyl derivatives of amphetamine were extracted into hexane. Extracts were dried, reconstituted in the mobile phase, and injected onto a chiral, high-performance liquid chromatography column (Chiralcel^®^ OB-H 5 µm, 4.6 × 150 mm with a guard of Chiralcel^®^ OB 10 µm, 4.6 × 50 mm). After separation of the analytes, ammonium formate was introduced as a post-column addition to improve analyte ionization. All compounds were detected by operating the system in multiple reaction monitoring mode. The transitions monitored were *m/z* 240 → 91 for amphetamine and *m/z* 246 → 93 for the deuterated amphetamine. Micromass MassLynx™, Version 4.0 (Waters Corporation, Milford, MA, USA) software was used for data acquisition.

### Safety and Tolerability {#Sec8}

Safety and tolerability measures included assessments of treatment-emergent AEs (TEAEs) and vital signs. Vital signs (including pulse, SBP, and DBP) were collected after the participant had been seated for 5 min at 30 min pre-dose (hour 0) and 2, 4, 8, 12, 24, and 60 h post-dose. Twelve-lead electrocardiograms were obtained following 5 min of rest at hour 0 and at 2, 4, 8, 12, 24, and 60 h post-dose. The occurrence of AEs and use of concomitant medications were recorded throughout each treatment period.

Data and Statistical Analyses {#Sec9}
-----------------------------

A formal sample size calculation was not performed for this study owing to limited data being available for estimation at the time the study was conducted. Pharmacokinetic analyses were conducted in the pharmacokinetic population, defined as all participants who received one or more doses of SHP465 MAS and who had evaluable concentration--time profiles for *d-* or *l-*amphetamine. Pharmacokinetic parameters are reported descriptively and were analyzed using analysis of variance with sequence, period, and treatment as fixed effects and participant nested within a sequence as a random effect; natural log transformations were used to assess *C*~max~, AUC~0--inf~, and AUC~0--last~. Exponentiated least-squares mean (LSM) for each treatment were obtained for *C*~max~, AUC~0--inf~, and AUC~0--last~, and the ratios of the exponentiated LSM with 90% confidence intervals for each test condition (fed and sprinkled) relative to the reference condition (fasted) were calculated. If the 90% confidence intervals for the LSM ratio fell within the range of 80--125%, it was considered to indicate the absence of an effect of consuming a high-fat meal or of sprinkling the capsule contents onto applesauce on the bioavailability of SHP465 MAS relative to the fasted state. Statistical analyses were conducted using SAS (SAS Institute Inc., Cary, NC, USA).

Safety and tolerability endpoints were assessed in the safety population, defined as all participants who received one or more SHP465 MAS doses during the study. Safety and tolerability data are reported using descriptive statistics.

Results {#Sec10}
=======

Participant Disposition and Demographics {#Sec11}
----------------------------------------

All 16 enrolled participants were included in the safety population and pharmacokinetic population. Fourteen participants completed the study, with two participants discontinuing because of an AE (one case of vomiting that occurred 8 days after receiving the second treatment \[50 mg of SHP465 sprinkled over applesauce\] that was considered to be of mild intensity and not related to the study drug; one case of anxiety that occurred in the afternoon following the second treatment \[50 mg of SHP465 sprinkled over applesauce\] that was considered to be of mild intensity and probably related to the study drug). Table [1](#Tab1){ref-type="table"} summarizes participant demographics and clinical characteristics.Table 1Participant demographic and baseline clinical characteristics, safety populationCharacteristicsTotal (*n *= 16)Mean ± SD age, years32.8 ± 12.51Sex, *n* (%) Male9 (56.3) Female7 (43.8)Race, *n* (%) White15 (93.8) Black/African American1 (6.3)Mean ± SD weight, kg73.7 ± 10.16Mean ± SD height, cm173.8 ± 11.62Mean ± SD BMI, kg/m^2^24.46 ± 2.049*BMI* body mass index, *SD* standard deviation

Pharmacokinetics {#Sec12}
----------------

Plasma concentration--time curves for *d-* and *l-*amphetamine under each treatment condition are shown in Fig. [2](#Fig2){ref-type="fig"}. Both *d*- and *l*-amphetamine were quantifiable at 1-h post-dose and peaked between 7 and 8 h post-dose under the fasted and sprinkled treatment conditions. Under the fed treatment condition, amphetamine concentrations peaked at approximately 12 h and were lower than under the fasted and sprinkled treatment conditions.Fig. 2**a** *d*-Amphetamine and **b** *l*-amphetamine plasma concentration--time curves with 50 mg of SHP465 mixed amphetamine salts (MAS), pharmacokinetic population^a^. Fasted condition: 50 mg of SHP465 MAS as an intact capsule after a fast of ≥ 10 h. Fed condition: 50 mg of SHP465 MAS as an intact capsule 30 min following the start of a high-fat meal. Sprinkled condition: contents of a 50-mg SHP465 MAS capsule sprinkled on applesauce after a fast of ≥ 10 h. ^a^Data are the geometric mean ± the geometric standard deviation (SD)

Pharmacokinetic endpoints across treatment conditions are summarized descriptively for *d*- and *l-*amphetamine in Table [2](#Tab2){ref-type="table"}. Consistent with observations based on the plasma concentration--time curves, relative to the fasted (reference) treatment condition, consuming a high-fat meal prolonged median *t*~max~ for *d*-amphetamine by 5 h (from 7 to 12 h) and for *l*-amphetamine by 4.5 h (from 7.5 to 12 h). Median *C*~max~ for *d*-amphetamine (60.28 ng/mL) and *l*-amphetamine (17.32 ng/mL) also tended to be lower after a high-fat meal compared with the fasted condition (70.32 and 20.45 ng/mL, respectively), but *C*~max~ concentrations were largely overlapping. Based on exponentiated LSM (90% confidence interval) ratios for *C*~max~, AUC~0--inf~, and AUC~0--last~, neither a high-fat meal nor sprinkling the contents of a 50-mg SHP465 MAS capsule on applesauce altered *d*- or *l*-amphetamine exposure relative to the fasted treatment condition (Table [3](#Tab3){ref-type="table"}).Table 2Pharmacokinetic parameters by treatment, pharmacokinetic population^a^*C*~max~, ng/mLAUC~0--inf~, h·ng/mLAUC~0--last~, h·ng/mL*t*~max~, h*t*~½~, h*λ* ~*z*~*d*-Amphetamine Fed^b^ (*n* = 16)  Mean59.61400136012 (8.0--14.0)10.40.0669  CV%11.721.919.816.3318.218.2 Sprinkled^c^ (*n* = 16)  Mean66.9147014307.5 (5.0--9.0)10.40.0668  CV%11.618.816.818.4719.319.3 Fasted^d^ (*n* = 14)  Mean71.2156015107 (6.0--10.0)10.70.0651  CV%18.020.718.015.6322.222.2*l*-Amphetamine Fed^b^ (*n* = 16)  Mean17.446643712 (8.0--14.0)12.50.0555  CV%12.326.422.715.6324.324.3 Sprinkled^c^ (*n* = 16)  Mean19.84974708 (5.0--12.0)12.70.0546  CV%12.624.321.023.1422.822.8 Fasted^d^ (*n* = 14)  Mean20.85294977.5 (6.0--12.0)13.10.0527  CV%16.925.220.725.9526.426.4*AUC*~*0--inf*~ area under the plasma concentration--time curve from time 0 to infinity, *AUC*~*0--last*~ area under the plasma concentration--time curve from time 0 to the last measured time, *C*~*max*~ maximum plasma concentration, *CV%* percent coefficient of variation, *λ*~*z*~ terminal phase rate constant, *MAS* mixed amphetamine salts, *t*~*½*~ terminal half-life, *t*~*max*~ time to *C*~*max*~^a^Data are geometric mean and geometric CV%, except for *t*~max~, which is the median (minimum--maximum) and CV%^b^50 mg of SHP465 MAS as an intact capsule 30 min following the start of a high-fat meal^c^50 mg of SHP465 MAS after a fast of ≥ 10 h when the contents of the capsule were sprinkled on applesauce^d^50 mg of SHP465 MAS as an intact capsule after a fast of ≥ 10 h (reference condition) Table 3Exponentiated least-squares means (LSM) and ratios by treatment, pharmacokinetic population*C*~max~, ng/mLAUC~0--inf~, h·ng/mLAUC~0--last~, h·ng/mLExponentiated LSMRatio (90% CI) of exponentiated LSMExponentiated LSMRatio (90% CI) of exponentiated LSMExponentiated LSMRatio (90% CI) of exponentiated LSM*d*-Amphetamine Fed^a^ (*n* = 16)59.485.33 (80.44--90.50)1392.591.11 (86.69--95.75)1350.390.98 (86.71--95.46) Sprinkled^b^ (*n* = 16)66.795.76 (90.28--101.57)1463.795.77 (91.13--100.65)1424.595.97 (91.47--100.70) Fasted^c^ (*n* = 14)69.6NA1528.3NA1484.2NA*l-*Amphetamine Fed^a^ (*n* = 16)17.485.22 (80.18--90.59)463.488.74 (83.89--93.87)436.188.61 (83.85--93.65) Sprinkled^b^ (*n* = 16)19.896.90 (91.16--103.00)495.094.78 (89.60--100.26)468.195.12 (90.00--100.52) Fasted^c^ (*n* = 14)20.4NA522.3NA492.2NA*AUC*~*0--inf*~ area under the plasma concentration--time curve from time 0 to infinity, *AUC*~*0--last*~ area under the plasma concentration--time curve from time 0 to the last measured time, *CI* confidence interval, *C*~*max*~ maximum plasma concentration, *MAS* mixed amphetamine salts, *NA* not applicable^a^50 mg of SHP465 MAS as an intact capsule 30 min following the start of a high-fat meal^b^50 mg of SHP465 MAS after a fast of ≥ 10 h when the contents of the capsule were sprinkled on applesauce^c^50 mg of SHP465 MAS as an intact capsule after a fast of ≥ 10 h (reference condition)

Safety and Tolerability {#Sec13}
-----------------------

No deaths or serious AEs occurred during the study. Most study participants (14/16; 87.5%) reported one or more TEAE. All TEAEs were of mild or moderate intensity. No serious TEAEs were reported. Of the two participants who withdrew from the study because of AEs, only one instance (a case of anxiety in a participant under the sprinkled treatment condition) was considered to be a TEAE. Treatment-emergent adverse events reported by two or more participants across any treatment condition are summarized in Table [4](#Tab4){ref-type="table"}. The most frequently reported TEAEs were anorexia, headache, increased energy, and dry mouth.Table 4Treatment-emergent adverse events (TEAEs) by treatment condition, safety populationTEAEsFasted^a^ (*n* = 14)Fed^b^ (*n* = 16)Sprinkled^c^ (*n* = 16)Participants with ≥ 1 TEAE, *n* (%)8 (57.1)8 (50.0)10 (62.5)TEAEs reported by ≥ 2 participants across treatment conditions, *n* (%)Anorexia1 (7.1)5 (31.3)3 (18.8)Headache2 (14.3)3 (18.8)3 (18.8)Energy increased2 (14.3)1 (6.3)3 (18.8)Dry mouth02 (12.5)2 (12.5)Anxiety1 (7.1)02 (12.5)Nausea1 (7.1)1 (6.3)1 (6.3)Circumoral paresthesia1 (7.1)1 (6.3)1 (6.3)Tremor1 (7.1)1 (6.3)1 (6.3)Insomnia1 (7.1)1 (6.3)1 (6.3)Blood pressure increased1 (7.1)1 (6.3)0Palpitations1 (7.1)1 (6.3)0Feeling jittery002 (12.5)Dizziness2 (14.3)00*MAS* mixed amphetamine salts^a^50 mg of SHP465 MAS as an intact capsule after a fast of ≥ 10 h (reference condition)^b^50 mg of SHP465 MAS as an intact capsule 30 min following the start of a high-fat meal^c^50 mg of SHP465 MAS after a fast of ≥ 10 h when the contents of the capsule were sprinkled on applesauce

The magnitude of mean pulse changes was comparable across treatment conditions, with maximum mean ± standard deviation increases being observed at 12 h post-dose across all conditions (fasted: 25.6 ± 11.06 bpm; fed: 23.9 ± 13.24 bpm; sprinkled: 28.3 ± 18.70 bpm). Increases in SBP tended to be lower under the fed condition compared with the other treatment conditions; the maximum mean ± standard deviation increase in SBP was observed at 2 h post-dose in the fasted condition (23.0 ± 14.28 mmHg) and at 8 h post-dose in the fed (15.9 ± 11.12 mmHg) and sprinkled (23.4 ± 14.21 mmHg) conditions. Increases in DBP also tended to be lower under the fed condition compared with the other treatment conditions; the mean ± maximum increase in DBP was observed at 2 h post-dose in the fasted condition (11.7 ± 6.70 mmHg), at 4 h post-dose in the sprinkled condition (6.4 ± 8.95 mmHg), and at 8 and 12 h post-dose (6.8 ± 7.01 and 6.8 ± 7.69, respectively) in the fed condition.

Discussion {#Sec14}
==========

The purpose of this study was to evaluate the pharmacokinetics of *d*- and *l*-amphetamine when 50 mg of SHP465 MAS was administered following a high-fat meal or after the contents of a 50-mg SHP465 MAS capsule was sprinkled on applesauce compared with administration following a 10-h fast. The results indicate that exposure to *d*- and *l*-amphetamine is not altered by consumption of a high-fat meal before SHP465 MAS administration or by sprinkling the contents of an SHP465 MAS capsule on applesauce before ingestion. This demonstrates that SHP465 MAS can be swallowed whole with or without food or the contents of an SHP465 MAS capsule can be sprinkled on applesauce. This is consistent with reports for other ADHD medications \[[@CR16]--[@CR19]\], one of which is extended-release MAS, \[[@CR16]\] which have also indicated that amphetamine or methylphenidate exposure is not significantly altered by consumption of a high-fat meal or by sprinkling/mixing the contents of capsules with a soft food \[[@CR16]--[@CR19]\].

Consumption of a high-fat meal delayed median *t*~max~ for *d*- and *l*-amphetamine relative to the fasted condition by 5 h and 4.5 h, respectively. This finding is consistent with a previous study of MAS extended release that reported delays in *t*~max~ of 2 and 3 h for *d*- and *l*-amphetamine, respectively, after a high-fat meal \[[@CR16]\]. It is also consistent with a published report of extended-release orally disintegrating amphetamine, which reported delayed *t*~max~ of 2 and 2.25 h for *d*- and *l*-amphetamine, respectively, after a high-fat high-calorie meal \[[@CR20]\]. The median *t*~max~ and ranges for *d*- and *l*-amphetamine were the same under the fed condition and were similar under the fasted and sprinkled conditions. The small differences observed across conditions is not expected to have any clinical impact based on the pharmacological potency of *d*- and *l*-amphetamine. The observed *t*~max~ values for the fasted and sprinkled conditions are also generally consistent with those reported by Ermer et al. \[[@CR21]\]. There were no observed treatment differences for elimination of *d*- or *l*-amphetamine, as measured by *t*~½~ or *λ*~*z*~, indicating that administration of SHP465 MAS with a meal did not alter the elimination characteristics of either enantiomer.

The safety and tolerability profile of 50 mg of SHP465 MAS in healthy adults in this study was generally consistent with previous observations from short-term phase III studies of SHP465 in adults with ADHD \[[@CR2]--[@CR4]\] and for other amphetamine-based psychostimulants in healthy adults \[[@CR16], [@CR17], [@CR19], [@CR20]\] and adults with ADHD \[[@CR22], [@CR23]\]. The most frequently reported TEAEs in this study were anorexia, headache, increased energy, and dry mouth. The most frequently reported TEAEs in healthy adults included decreased appetite, dry mouth, palpitations, and headache with lisdexamfetamine \[[@CR17], [@CR19]\] and insomnia, headache, nausea, and dizziness with MAS extended release \[[@CR16]\]. Across phase III studies of SHP465 MAS in adults with ADHD, the most frequently reported TEAEs included decreased appetite, dry mouth, insomnia, and headache \[[@CR2]--[@CR4]\]. Mean pulse and blood pressure increased following SHP465 MAS treatment across all treatment conditions, although smaller magnitude blood pressure increases were observed during the fed condition than during the fasted and sprinkled conditions. As with the TEAE profile of SHP465 MAS, the observed increases in pulse and blood pressure are consistent with findings from phase III studies of SHP465 MAS in adults with ADHD \[[@CR2]--[@CR4]\] and from studies of other psychostimulants in healthy adults \[[@CR16], [@CR17], [@CR19]\]. Although the effects of SHP465 MAS on vital signs were expected and did not lead to clinically relevant events, it is recommended that vital signs be monitored regularly during treatment with psychostimulants \[[@CR24], [@CR25]\]. The time course of changes in blood pressure and heart rate observed in the current study, with increases in blood pressure peaking earlier than increases in heart rate, has been observed in studies of SHP465 MAS \[[@CR21]\] and other psychostimulants \[[@CR17], [@CR26]\]. At this time, the mechanisms responsible for this pattern of changes are not known. However, the differential time course of changes was small, transitory, and not expected to be clinically important.

These data should be considered in light of several limitations. First, the safety and tolerability findings from this phase I study should be interpreted with caution because of the small sample size and the short duration of exposure. Furthermore, because of the nature of this single-dose study, it cannot be determined if differences in bioavailability would be observed between administration conditions with other SHP465 MAS doses.

Conclusions {#Sec15}
===========

Exposure to *d*- and *l*-amphetamine following 50 mg of SHP465 MAS was not altered by consumption of a high-fat meal or by sprinkling the contents of a capsule over applesauce, as measured by *C*~max~, AUC~0--inf~, and AUC~0--last~. This demonstrates that SHP465 MAS capsules can be swallowed whole with or without food and that the contents of a capsule can be added to a spoonful of applesauce and immediately consumed. The ability to take SHP465 MAS with or without food or by sprinkling the contents of a capsule on applesauce allows for flexibility in administration and eases administration difficulties for individuals who are unable to swallow a tablet or capsule. SHP465 MAS was generally well tolerated when administered as a single 50-mg dose in healthy adults.
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